Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 6/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360245 | 0.81 | NPC1 (0.50) | NPC1KIF11NOTUMKDM4EALDH1A1 | |
| SCHEMBL5945906 | 0.80 | NOTUM (0.56) | NPC1NOTUMKDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL345941 | 0.79 | NPC1 (0.54) | NPC1NOTUMKDM4EPOLBHSD17B10 | |
| SCHEMBL3620750 | 0.77 | NOTUM (0.48) | KIF11NOTUMCYP1A2SMN1; SMN2NPSR1 | |
| SCHEMBL1550945 | 0.76 | PKM (0.52) | NPC1NOTUMKDM4EALDH1A1CYP1A2 | |
| SCHEMBL344372 | 0.75 | NPC1 (0.46) | NPC1NOTUMKDM4EALDH1A1CYP1A2 | |
| SCHEMBL209522 | 0.75 | RAB9A (0.54) | NPC1NOTUMKDM4EALDH1A1POLB | |
| SCHEMBL8631839 | 0.75 | RAB9A (0.43) | NPC1ALDH1A1POLBHSD17B10SMN1; SMN2 | |
| SCHEMBL7223282 | 0.75 | NPC1 (0.47) | NPC1NOTUMKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7301794 | 0.75 | NPC1 (0.46) | NPC1NOTUMKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015028989-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-05 | — | — | WO | claimed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | claimed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | claimed |
| CN-110846675-B | Synthetic method of 2- (5-aryl-1, 3, 4-oxadiazole-2-yl) aniline compound | 阜阳师范大学 | 2021-05-28 | — | — | CN | disclosed |
| CN-110846675-A | Synthetic method of 2- (5-aryl-1, 3, 4-oxadiazole-2-yl) aniline compound | 阜阳师范大学 | 2020-02-28 | — | — | CN | disclosed |
| WO-2015028989-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-05 | — | — | WO | disclosed |
| US-7101880-B2 | Peptidic compounds as cysteine protease inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| WO-2004000838-A1 | PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| US-5773456-A | EMPHYSEMA, RHEUMATOID ARTHRITIS AND PANCREATITIS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5578623-A | DRUGS FOR TREATMENT OF ARTHRITIS, PANCREATITIS, CYSTIC FIBROSIS, BRONCHITIS, RESPIRATORY DISORDERS | STERLING WINTHROP INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5464852-A | Used in treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5380737-A | Enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0542371-A1 | Saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | NPC1 284/4885KIF11 3241/4885NOTUM 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.